Corporate Presentation – Remium Health Care Capital Market Day

Dec 2, 2013

Peter Wolpert, CEO and Founder

Moberg Pharma AB A DIFFERENT KIND OF PHARMA COMPANY

Disclaimer

1

Statements included herein that are not historical

facts are forward-looking statements. Such forward-

looking statements involve a number of risks and

uncertainties and are subject to change at any time.

In the event such risks or uncertainties materialize,

Moberg Pharma’s results could be materially

affected.

The risks and uncertainties include, but are not

limited to, risks associated with the inherent

uncertainty of pharmaceutical research and product

development, manufacturing and commercialization,

the impact of competitive products, patents, legal

challenges, government regulation and approval,

Moberg Pharma’s ability to secure new products for

commercialization and/or development and other

risks and uncertainties detailed from time to time in

Moberg Pharma’s interim or annual reports,

prospectuses or press releases.

2

Moberg Pharma Building a different kind of pharma company

Strategic plan

Strategy to reach1 BSEK

in sales

Focus on shareholder value

Organic growth, M&A and

internal development

Build value through:

- Brand Equity, U.S. focus

- IP Equity

Vision

Build a mid-size Pharma and

Consumer Health company with

sales in the U.S. and select countries

in OTC and select specialty

indications

Financial goal

25% EBITDA margin with healthy

growth

Fourteen consecutive quarters of sales growth

Product Sales, MSEK

3

0

20

40

60

80

100

120

140

160

Q12010

Q22010

Q32010

Q42010

Q12011

Q22011

Q32011

Q42011

Q12012

Q22012

Q32012

Q42012

Q12013

Q22013

Q32013

Majority of revenue from Direct Sales

4

Sales via distributors

40%

Direct Sales 60%

JointFlex 19%

Nalox/ Kerasal Nail

65%

Kerasal 16%

RoW 10%

Europe 29%

America 61%

Channels Products Geography

Distribution of revenue, Jan - Sept 2013

Portfolio of Brands, Products and Projects

Current portfolio Future portfolio

Brands

Products sold

through partners

Pipeline

® ®

®

5

MOB-015

X Y Z +

X Y +

Platform for building Brand Equity - U.S OTC operations

Retailers/

Wholesalers Sales Force

Contract

Manufacturers

Logistics

Sales and marketing/Brand Management

6

A large aging population, steady to increased incidences of conditions and diseases, self

care & Rx to OTC switches fuel OTC market growth

U.S. Consumer spending on OTC health is expanding

Source: Nielsen Scantrack Total US xAOC 52 weeks ending CY2012. Projected estimate for 2013/2014 based on current growth rate.

$37,2 $38,4

$40,1

$42,1

$44,3

12/25/10 12/24/11 12/22/12 est. 2013 est. 2014

Total US Sales (billions)

+4.5% +3.2%

+4.9% +5.2%

7

CONFIDENTIAL

8

Q3 growth (Value), percent

5%

26%

OTC market

Moberg U.S.

Significantly faster growth

than the market

Growth driver

Combination of Brand and

IP equity:

Available at 30 000 points of sale

Distribution added through Target,

Meijer and Hannaford

9

10% 19% market share increase last 12 months

Kerasal Nail™ – Best selling product in its category

10

Positive initial response on advertising and

the product from consumers and retailers

Walgreens increases distribution

21,000 stores at Walmart, CVS,

Walgreens, and Rite Aid

Ca 30 million Americans experience

frequent foot pain1. Many simultaneously

suffer from cold feet and dry skin.

Associated with diabetes, fibromyalgia,

arthritis, joint pain, muscle strain or trauma.

Triple action formula that relieves foot pain,

warms cold feet, and moisturizes dry skin.

Active ingredients: capsaicin and camphor,

Fusome® - skin delivery system

Launch of Kerasal® NeuroCream at Walmart and major U.S.

drugstores in September 2013

1 The population prevalence of foot and ankle pain in middle and old age: a systematic review. Thomas et al, Pain 2011 Dec

11

Organic growth

Current products growing, line extensions

- Kerasal NeuroCream™ launch started

Launches in new markets through

distributors

8 patent families enable additional products

- MOB-015

>100 NEW BUSINESS OPPORTUNITIES TO BE EVALUATED 2013 Acquisitions/inlicensing

Products - Focus on US OTC market

Projects and technologies

MOB 015 generates high TBF concentrations in nail

Phase II trial ongoing (fully recruited, final data Q4 2014)

12

Target profile for MOB-015

Low Medium High

High

Medium

Low

Efficacy

Existing

tablets MOB-015

Nalox™

Existing

topicals

Safety

Source: Hui, Maibach et al, Drug Development and Industrial Pharmacy, 2012; Franz cell experiments with human nail;

Amount TBF in the deeper part of the nail plate

** Schatz F, et al; Clin Exp Dermatol, 1995 Sep;20(5):377-83

Terbinafine concentration in human nail, µg/g nail

0,5

> 613

Oral terbinafine therapy** MOB-015*

Share development – from IPO to Nov 29, 2013 CONFIDENTIAL

13

14

Focus next 12 months Building a different kind of pharma company

Get to positive EBITDA!

Fuel strong U.S growth

- K-Nail and Neurocream launch

- Acquisitions of mature brands

Grow Distributor Sales

- Support current distributors

- Increase geographical reach

BD focus

- US OTC products

- Strengthen pipeline

MOB-015 phase II data & initiate licensing process